Woessner S, Asensio A, Florensa L, Pedro C, Besses C, Sans-Sabrafén J
Hematology and Oncology Unit 1973, Hospital Central de L'Aliança, Barcelona, Spain.
Leuk Lymphoma. 1994 May;13(5-6):457-61. doi: 10.3109/10428199409049635.
We investigated the expression of the lymphocyte function associated (LFA)-1 adhesion molecule, recognized by the CD11a and CD18 monoclonal antibodies, in 53 patients with B-cell chronic lymphocytic leukemia (B-CLL) and in 37 controls. The mean percentage of control lymphocytes expressing CD11a and CD18 positivity was 92 +/- 5.5 and 90 +/- 8.7, respectively and, in patients with B-CLL, 14.2 +/- 10.3 and 14.8 +/- 10.3 respectively (p < 0.001). No statistical difference was found between CD11a and CD18 expression and the Rai clinical stages. In our experience a decrease of LFA-1 is a constant finding in B-CLL, in the early stages of the disease. It may, therefore, be useful to differentiate between slight increases of neoplastic cells and reactive blood lymphocytosis.
我们研究了53例B细胞慢性淋巴细胞白血病(B-CLL)患者和37名对照者中由CD11a和CD18单克隆抗体识别的淋巴细胞功能相关(LFA)-1黏附分子的表达情况。对照淋巴细胞表达CD11a和CD18阳性的平均百分比分别为92±5.5和90±8.7,而在B-CLL患者中分别为14.2±10.3和14.8±10.3(p<0.001)。CD11a和CD18表达与Rai临床分期之间未发现统计学差异。根据我们的经验,在疾病早期,B-CLL中LFA-1降低是一个持续存在的现象。因此,这可能有助于区分肿瘤细胞的轻微增加和反应性血液淋巴细胞增多。